Publication Author: Sullivan_Sean
-
Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300Â U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study.
Sullivan SD, Freemantle N, Gupta RA, Wu J, Nicholls CJ, Westerbacka J, Bailey TS. Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the Uni
rakerr2
-
Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme.
Blonde L, Bailey T, Sullivan SD, Freemantle N. Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme. Diabetes Obes Metab. 2021 Aug;23(8):1713-1721. doi: 10.1111/dom.14405.
rakerr2
-
Are Drugs Priced in Accordance With Value? A Comparison of Value-Based and Net Prices Using Institute for Clinical and Economic Review Reports.
Bloudek LM, Nguyen V, Grueger J, Sullivan SD. Are Drugs Priced in Accordance With Value? A Comparison of Value-Based and Net Prices Using Institute for Clinical and Economic Review Reports. Value Health. 2021 Jun;24(6):789-794. doi: 10.1016/j.jval.2021.01
rakerr2
-
Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder.
Ta JT, Sullivan SD, Tung A, Oliveri D, Gillard P, Devine B. Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder. J Manag Care Spec Pharm. 2021 Feb;27(2):223-239. doi: 1
rakerr2
-
Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson’s disease patients treated with levodopa/carbidopa.
Hansen RN, Suh K, Serbin M, Yonan C, Sullivan SD. Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson’s disease patients treated with levodopa/carbidopa. J Med Econ. 2021 Jan-Dec;24(1):563-569. doi: 10.1080/13696998.2021.19167
rakerr2
-
THE AUTHORS RESPOND.
Roth JA, Carlson JJ, Xia F, Williamson T, Sullivan SD. THE AUTHORS RESPOND. J Manag Care Spec Pharm. 2020 Dec;26(12):1617-1618. doi: 10.18553/jmcp.2020.26.12.1617.
rakerr2
-
The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
Roth JA, Carlson JJ, Xia F, Williamson T, Sullivan SD. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer. J Manag Care Spec Pharm. 2020 Aug;26(8):981-
rakerr2
-
A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study.
Meneghini LF, Sullivan SD, Oster G, Busch R, Cali AMG, Dauchy A, Gill J, Bailey TS. A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcom
rakerr2
-
Cost effectiveness and impact on quality of life of abobotulinumtoxinA and onabotulinumtoxinA in the treatment of children with lower limb spasticity in Canada.
Johnston K, Danchenko N, Hansen R, Dinet J, Liovas A, Armstrong A, Bains S, Sullivan SD. Cost effectiveness and impact on quality of life of abobotulinumtoxinA and onabotulinumtoxinA in the treatment of children with lower limb spasticity in Canada. J Med
rakerr2
-
Pharmacoeconomic Evaluations: Guidelines for Drug Purchasers.
Langley PC, Sullivan SD. Pharmacoeconomic Evaluations: Guidelines for Drug Purchasers. J Manag Care Spec Pharm. 2020 Jun;26(6):689-695. doi: 10.18553/jmcp.2020.26.6.689.
rakerr2